← Innate Pharma SA (IPHYF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Innate Pharma SA (IPHYF)
Biotechnology · market cap $155M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
6
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Innate Pharma SA (IPHYF) is a French clinical-stage biotechnology company with 174 employees and a market cap of approximately $155M. The company operates a multi-asset pipeline spanning six Phase 2 programs across oncology and immunology indications, including lymphoma, AML, multiple myeloma, head and neck cancers, and secondary progressive multiple sclerosis. No upcoming catalysts are on the public calendar, and key financial metrics including cash position, runway, and dilution history are undisclosed in the provided data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MIS416 | Phase 2 | Secondary Progressive Multiple Sclerosis |
| IPH4102 | Phase 2 | Lymphoma, T-Cell |
| IPH6501 | Phase 2 | Non Hodgkin Lymphoma |
| IPH2101 | Phase 2 | Smoldering Multiple Myeloma |
| Monalizumab | Phase 2 | Head and Neck Neoplasms |
| IPH2102 at 0.1 mg/kg | Phase 2 | Acute Myeloid Leukemia |
Price & technical context
3-month
+0.0%
6-month
+20.4%
12-month
-17.5%
52-wk range
$1.37–$2.25
vs 50-day MA
-0.0%
vs 200-day MA
-8.4%
Realized vol
70.1%
Max drawdown
-55.9%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IPHYF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.